S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,691.01 +1.24%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,691.01 +1.24%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

ATAI

AtaiBeckley Inc. ATAI

$7.22 +0.07 (+0.98%)

Blow-off · +3.90σ Hot zone

+ Compare Open in Sniper

News · ATAI

Full news feed →

Why AtaiBeckley Stock Soared Today

The Motley Fool · 2d ago

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

GlobeNewswire Inc. · 12d ago

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

GlobeNewswire Inc. · 52d ago

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

GlobeNewswire Inc. · 87d ago

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

GlobeNewswire Inc. · 95d ago

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

GlobeNewswire Inc. · 123d ago

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

GlobeNewswire Inc. · 134d ago

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Benzinga · 141d ago

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

GlobeNewswire Inc. · 183d ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

GlobeNewswire Inc. · 191d ago

Why Atai Life Sciences Stock Was So Lively This Week

The Motley Fool · 274d ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

GlobeNewswire Inc. · 274d ago

atai Life Sciences Awarded Grant from the National Institutes of Health

GlobeNewswire Inc. · 303d ago

Atai Life Sciences Revenue Jumps 163%

The Motley Fool · 338d ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

GlobeNewswire Inc. · 382d ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

GlobeNewswire Inc. · 398d ago

HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Atai Life Sciences N.V. (NASDAQ: ATAI)

GlobeNewswire Inc. · 398d ago

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight

GlobeNewswire Inc. · 508d ago

5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

GlobeNewswire Inc. · 542d ago

4 Psychedelic Stocks to Consider as Clinical Trials Heat up

Investing.com · 711d ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

GlobeNewswire Inc. · 752d ago

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

GlobeNewswire Inc. · 758d ago

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment

Benzinga · 773d ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

GlobeNewswire Inc. · 778d ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

GlobeNewswire Inc. · 815d ago